Dronedarone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Dronedarone: From Atrial Fibrillation to Stroke Disorder
One-Sentence Summary
Dronedarone is a Class III antiarrhythmic originally used to maintain sinus rhythm in patients with paroxysmal or persistent atrial fibrillation (AF)/atrial flutter. The TxGNN model predicts it may also reduce the risk of stroke (a downstream complication of AF), with 19 clinical trials and 20 publications currently informing this direction — though the evidence is population-specific and includes a major safety caveat.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Atrial fibrillation / atrial flutter (sinus rhythm maintenance in paroxysmal or persistent AF) |
| Predicted New Indication | Stroke Disorder (stroke risk reduction in AF patients) |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L2 |
| Germany Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Dronedarone is a benzofuran derivative and non-iodinated analogue of amiodarone. It acts as a multi-channel blocker (sodium, potassium, calcium) with additional antiadrenergic activity, and is already approved for maintaining sinus rhythm in AF/atrial flutter.
The proposed new indication — stroke risk reduction — is not a separate disease area but a downstream consequence of the drug's approved mechanism: by lowering AF burden and restoring/maintaining sinus rhythm, dronedarone theoretically reduces atrial thrombus formation and the risk of cardioembolic (ischemic) stroke. This is not a novel target discovery; it reflects a class effect already partly captured in the pivotal ATHENA trial (Phase 3 RCT), whose post-hoc analyses suggested a reduction in stroke incidence among patients with paroxysmal/persistent AF. One mechanistic study (PMID 28992468) further suggests dronedarone may have direct anticoagulant/antiplatelet effects independent of its antiarrhythmic action, offering a possible additional pathway for stroke reduction.
However, this rationale has an important population boundary: the PALLAS trial (PMID 22082198, NCT01151137), conducted in patients with permanent AF and additional risk factors, found dronedarone increased stroke, myocardial infarction, and cardiovascular death, leading to early termination. This means the stroke-benefit signal applies specifically to paroxysmal/persistent AF, not permanent AF — a critical guardrail for any repurposing pathway.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01856075 | Observational | Completed | 1,015 | Real-world comparative effectiveness of dronedarone vs. other antiarrhythmic drugs for AF (Germany, Spain, Italy, USA) |
| NCT05130268 | Phase 4 | Completed | 339 | Pragmatic RCT of early dronedarone vs. usual care in first-detected AF |
| NCT01151137 | Phase 3 | Terminated | 3,236 | PALLAS trial — dronedarone 400mg BID added to standard therapy in permanent AF with risk factors; terminated early after dronedarone increased stroke, CV death, and hospitalization vs. placebo |
| NCT05279833 | Systematic review/NMA | Completed | 87,810 | Systematic literature review/network meta-analysis of dronedarone (Multaq®) vs. sotalol safety and effectiveness in AF |
| NCT04704050 | Phase 4 | Terminated | 22 | EDORA trial — dronedarone vs. placebo post-catheter ablation; assessed AF recurrence and atrial fibrosis progression |
| NCT07270848 | Phase 4 | Not yet recruiting | 1,898 | Planned multicenter study on efficacy, safety, and quality-of-life outcomes of dronedarone for early rhythm control |
| NCT07242326 | Observational | Enrolling by invitation | 1,000 | Registry assessing label-concordant dosing and adherence for oral anticoagulants/antiarrhythmics in elderly AF patients |
| NCT01266681 | N/A | Unknown | 100 | RCT comparing amiodarone vs. dronedarone for maintenance of sinus rhythm post-cardioversion |
| NCT01288352 | Phase 4 | Completed | 2,789 | EAST trial — early structured rhythm control (AADs incl. dronedarone + ablation) vs. usual care to prevent AF-related complications, including stroke |
| NCT05293080 | Phase 3 | Not yet recruiting | 1,746 | Planned RCT of early rhythm control therapy after acute ischemic stroke with AF to prevent recurrent cardiovascular events |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22082198 | 2011 | RCT | N Engl J Med | PALLAS trial: dronedarone in high-risk permanent AF increased risk of stroke, MI, and CV death; trial terminated early |
| 40387892 | 2025 | RCT (EAST-AFNET4 analysis) | Clin Res Cardiol | Long-term safety/efficacy of amiodarone and dronedarone for early rhythm control in the EAST-AFNET4 cohort |
| 28496906 | 2013 | Cohort | J Atrial Fibrillation | Real-world comparison: dronedarone vs. amiodarone/other AADs — risk of CV events, stroke, CHF, interstitial lung disease, liver injury |
| 37485722 | 2023 | Cohort | Circ Arrhythm Electrophysiol | Veterans database: dronedarone vs. sotalol effectiveness/safety head-to-head in AAD-naive AF patients |
| 35293087 | 2022 | Post-hoc analysis | Eur J Heart Fail | ATHENA post-hoc analysis: dronedarone in AF with HFpEF/HFmrEF |
| 22920480 | 2012 | Review | Curr Cardiol Rev | Stroke prevention in atrial fibrillation: concepts and controversies |
| 20730068 | 2010 | Review | Vasc Health Risk Manag | Dronedarone approval and efficacy, including post-hoc stroke risk reduction from ATHENA |
| 28992468 | 2017 | Mechanistic | Atherosclerosis | Dronedarone exerts anticoagulant/antiplatelet effects independent of its antiarrhythmic action |
| 24469871 | 2013 | Review | Cardiol J | Efficacy and tolerability of dronedarone in clinical practice for AF |
| 25428811 | 2015 | Pharmacoeconomic review | Kardiol Pol | Cost-effectiveness of dronedarone vs. amiodarone, propafenone, and sotalol (Serbia) |
Germany Market Information
Dronedarone is currently not marketed in Germany, and no active marketing authorizations were found in this evidence pack.
Safety Considerations
Please refer to the package insert for formal safety information — detailed warnings, contraindications, and drug interaction data were not available in this evidence pack (flagged as data gaps DG001/DG002 below).
That said, two important safety signals emerged directly from the clinical evidence reviewed:
- Permanent AF is a high-risk population: The PALLAS trial (NCT01151137) found that adding dronedarone to standard therapy in patients with permanent AF and additional risk factors increased stroke, MI, and cardiovascular death, leading to early termination. Any stroke-prevention benefit appears limited to paroxysmal/persistent AF.
- Digoxin interaction risk: A real-world data study (PMID 33888353) found that concomitant dronedarone and digoxin use is associated with increased risk of digitalis intoxication (likely via P-glycoprotein inhibition), warranting monitoring in patients on combined therapy.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple real-world cohort studies and ATHENA post-hoc analyses support a stroke-risk-reduction signal for dronedarone in paroxysmal/persistent AF, but the PALLAS trial demonstrates clear harm in permanent AF with additional risk factors — the predicted benefit is population-specific, not universal.
To proceed, the following is needed:
- Formal safety data: TFDA/EU package insert with warnings and contraindications (currently a Blocking data gap, DG001)
- Formal mechanism-of-action documentation from DrugBank (currently a High-severity data gap, DG002)
- A protocol that explicitly restricts the stroke-prevention claim to paroxysmal/persistent AF and excludes permanent AF
- A monitoring plan for known interactions (e.g., digoxin) and cardiac safety (heart rate/QT, hepatic function)
- Clarification of German market entry pathway, given the drug is not currently marketed there
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.